Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1629-1631

  Verbrugge, Inge ^a   Galli, Mara ^b   Smyth, Mark J ^b,c   Johnstone, Ricky W ^b,c   Haynes, Nicole M ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast cancer; CD137; CD40; Immunotherapy; PD 1; Radiotherapy; T cells

Indexed keywords

CALRETICULIN; CD134 ANTIGEN; CD137 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HIGH MOBILITY GROUP B1 PROTEIN; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; BREAST TUMOR; CANCER RADIOTHERAPY; DENDRITIC CELL; DNA DAMAGE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IONIZING RADIATION; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

EID: 84886943692     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21652     Document Type: Note

References (10)

1. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010; 15:411-21; PMID:21161342; http://dx.doi.org/10.1007/s10911-010-9194-9.
2. Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L. Prerequisites for the antitumor vaccinelike effect of chemotherapy and radiotherapy. Cancer J 2011; 17:351-8; PMID:21952286; http://dx.doi.org/10.1097/PPO.0b013e3182325d4d.
3. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824.
4. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163-74; PMID:22570253; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210.
5. Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol 2011; 187:1634-42; PMID:21742975; http://dx.doi.org/10.4049/jimmunol.1100077.
6. Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, et al. The HIF-1alpha Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. Cancer Discov 2012.
7. Dunn PL, North RJ. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukoc Biol 1991; 49:388-96; PMID:1900523.
8. Schatten S, Granstein RD, Drebin JA, Greene MI. Suppressor T cells and the immune response to tumors. Crit Rev Immunol 1984; 4:335-79; PMID:6232115.
9. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12:693-8; PMID:16680149; http://dx.doi.org/10.1038/nm1405.
10. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007; 220:82-101; PMID:17979841; http://dx.doi.org/10.1111/j.1600-065X.2007.00566.x.